Multimodality treatment in unresectable cholangiocarcinoma

Area of Science:

• Oncology
• Gastroenterology
• Radiotherapy

Background:

• Cholangiocarcinomas (CCs) are rare, highly malignant cancers.
• Effective treatment protocols for unresectable extrahepatic CCs (ECCs) are crucial for improving patient survival.
• Multimodality therapeutic protocols (MTPs) combine various treatments to address complex cancers.

Purpose of the Study:

• To investigate the survival rate of patients with unresectable ECCs receiving an MTP.
• To identify factors influencing survival time and treatment outcomes in these patients.

Main Methods:

• Retrospective study of 38 patients with unresectable ECCs diagnosed between 2012-2015.
• MTP included biliary drainage, external beam radiotherapy (EBRT) with concurrent chemotherapy (capecitabine), and brachytherapy (BT).
• Data collected included demographics, complications, laboratory tests, imaging, and survival times (overall survival and survival after catheter placement).

Main Results:

• Mean overall survival (OS) was 15.11 months; mean survival after catheter placement (CS) was 11.71 months.
• Patients with involvement of liver parenchyma, great vessels, regional lymph nodes, and Bismuth type IV had decreased OS and CS.
• The study included 57.9% male patients, with Bismuth-Corlette stages IIIA, IIIB, and IV.

Conclusions:

• An MTP can significantly improve survival time and reduce complications in patients with inoperable ECCs.
• Survival is significantly influenced by tumor staging, gender, and the extent of organ involvement (liver, vessels, lymph nodes).